This application is to support our participation in the multi- disciplinary and multi-institutional cooperative group clinical trials of Cancer and Acute Leukemia Group B. Since joining the CALGB 6 months ago, we have developed into active participants in both phase 2 and 3 studies and companion studies emphasizing laboratory investigation. The multidisciplinary studies of the group assist in bringing together these modalities at the University of Iowa itself. Cooperative group membership allows the University of Iowa investigators over the next 5 years to focus on innovative, small clinical trials (Phase 1/2 type trials appropriate for a single institution) while participating in controlled, randomized phase III trials not feasible within a single hospital. Further, the activities of the CALGB have initiated research at the University of Iowa utilizing biological response modifiers in a setting in which controlled comparisons can be made. Our specific goals in the next grant period include initiating for the group trials in salvage therapy for Hodgkin's and non-Hodgkin's lymphoma patients resistant to lst line therapies using intensive therapy and autologous bone marrow transplant support, trials using the immunology laboratory of the University of Iowa for assay of LAK cell activity and other immunologic parameters, trials using radiation sensitizers (such as Lonidamine) or endobronchial radiation as innovations in radiation therapy, and trials using differentiating agents (13-cis Retinoic Acid, Vitamin D3) based on phase I/II trial results at the University of Iowa. Through participation in groups trials we hope to advance the programs of the entire CALGB. Through pilot studies (such as MOPLEC for Hodgkin's disease or beta-Interferon and IL-2 for lymphoma) we will help develop newer therapies for future controlled trials. Through laboratory related companion studies, we will advance the basic science programs of other CALGB institutions. The multi- disciplinary programs of the CALGB will contribute over the next 5 years to the training of both fellows and residents at the University of Iowa. Through the development of 3 affiliate programs, quality multidisciplinary cancer care will be fostered in Iowa, a rural state with few large cancer programs. Our accrual should be approximately 100 patients per year from the University of Iowa Hospital system and 20 more patients in addition per year from our 3 affiliates.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA047642-05
Application #
3558815
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1988-04-01
Project End
1993-03-31
Budget Start
1992-04-01
Budget End
1993-03-31
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
Schools of Medicine
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Fuchs, Charles S; Niedzwiecki, Donna; Mamon, Harvey J et al. (2017) Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol 35:3671-3677
Martin, Linda W; D'Cunha, Jonathan; Wang, Xiaofei et al. (2016) Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). J Clin Oncol 34:1484-91
Morrison, Vicki A; Jung, Sin-Ho; Johnson, Jeffrey et al. (2015) Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma 56:958-64
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Wang, Xiaofeng; Owzar, Kouros; Gupta, Pankaj et al. (2014) Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol 78:1005-13
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11

Showing the most recent 10 out of 110 publications